CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 500 filers reported holding CRISPR THERAPEUTICS AG in Q2 2021. The put-call ratio across all filers is 1.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $20,190,000 | -32.3% | 266,430 | 0.0% | 0.57% | -23.3% |
| Q3 2021 | $29,822,000 | -30.9% | 266,430 | 0.0% | 0.74% | -32.2% |
| Q2 2021 | $43,132,000 | +32.9% | 266,430 | 0.0% | 1.10% | +13.2% |
| Q1 2021 | $32,464,000 | -20.4% | 266,430 | 0.0% | 0.97% | -20.0% |
| Q4 2020 | $40,793,000 | +83.1% | 266,430 | 0.0% | 1.21% | +21.1% |
| Q3 2020 | $22,284,000 | +13.8% | 266,430 | 0.0% | 1.00% | -13.9% |
| Q2 2020 | $19,580,000 | +73.3% | 266,430 | 0.0% | 1.16% | -3.3% |
| Q1 2020 | $11,299,000 | +15.8% | 266,430 | +21.1% | 1.20% | +1.1% |
| Q3 2018 | $9,757,000 | -24.5% | 220,000 | 0.0% | 1.19% | -34.4% |
| Q2 2018 | $12,927,000 | +109.5% | 220,000 | +63.0% | 1.81% | +66.6% |
| Q1 2018 | $6,171,000 | – | 135,000 | – | 1.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |